Absci Corporation (ABSI)
NASDAQ: ABSI · Real-Time Price · USD
2.960
+0.030 (1.02%)
At close: May 13, 2025, 4:00 PM
3.380
+0.420 (14.19%)
Pre-market: May 14, 2025, 9:15 AM EDT
Company Description
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.
The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics.
Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin for joint research and development activities.
The company was founded in 2011 and is headquartered in Vancouver, Washington.
Absci Corporation
| Country | United States |
| Founded | 2011 |
| IPO Date | Jul 22, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 157 |
| CEO | Sean McClain |
Contact Details
Address: 18105 SE Mill Plain Boulevard Vancouver, Washington 98683 United States | |
| Phone | 360 949 1041 |
| Website | absci.com |
Stock Details
| Ticker Symbol | ABSI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001672688 |
| CUSIP Number | 00091E109 |
| ISIN Number | US00091E1091 |
| Employer ID | 85-3383487 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Sean McClain | Founder, Chief Executive Officer, President and Director |
| Dr. Zachariah Jonasson Ph.D. | Chief Business Officer and Chief Financial Officer |
| Dr. Andreas Busch Ph.D. | Chief Innovation Officer and Member of Scientific Advisory Board |
| Todd Bedrick CPA | Senior Vice President and Chief Accounting Officer |
| Alexander Khan CPA | Vice President of Finance and Head of Investor Relations |
| Shelby Walker J.D. | Chief Legal Officer |
| Karin Wierinck | Chief People Officer |
| Melissa Patterson Ph.D. | Chief of Staff |
| Wen Sha | Chief of Staff |
| Dr. Christine Lemke D.V.M., M.B.A., Ph.D. | Senior Vice President of Portfolio and Growth Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| Apr 29, 2025 | SCHEDULE 13D/A | Filing |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 11, 2025 | 424B3 | Prospectus |
| Apr 10, 2025 | EFFECT | Notice of Effectiveness |